Neuroscience startup Vima Therapeutics extended its Series A by $40 million, bringing total funding to $100 million to advance VIM0423, its trihexyphenidyl‑based muscarinic antagonist formulation. The company said it will use the capital to complete two Phase II trials in isolated dystonia and Parkinson’s disease after early clinical data validated target engagement and tolerability. Investors that joined the extension include Atlas Venture, Frazier Life Sciences and others. Vima is positioning VIM0423 as a differentiated muscarinic blocker paired with bethanechol to mitigate peripheral side effects, with the company citing shared hypercholinergic biology across dystonia and Parkinson’s as a rationale for expanding the program.